Gilead Sciences

Biotechnology
GILD
$ 63 1.4
Share price
$ 79 bn
Market Cap
$ 102 bn
Enterprise Value

Carbon footprint

0.83 Ton
GHG emissions per $ 1 mln investment
0.03x the weighted average for S&P 500
FY2020
How is this calculated?
+16%
YOY change in GHG emissions
Weaker than the -8.7% weighted average for S&P 500
FY2020 vs. previous year

Primary Climate Goal

-5.4%
Proj. YOY change in GHG emissions (Scope 1 + 2)
In line with the -5.1% weighted average for S&P 500
FY2021
How is this calculated?

Gilead Sciences aims to reduce Scope 1 + 2 by 46% by 2030 from a base year 2019


1.5°C
Gilead Sciences's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

Secondary Climate Goal

Gilead Sciences aims to reduce Scope 3 by 15% by 2030 from a base year 2019


1.5°C

GHG emissions and Carbon intensity

Gilead Sciences's GHG emissions (market-based) (Kt of CO2e)
Gilead Sciences's Carbon intensity (Tons per 1 USDm)

Gilead Sciences's carbon footprint

Gilead Sciences reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 84 Kt (+12/+16% y-o-y). Carbon intensity also was up at 3.4 t (+0.2/+6.2% y-o-y).

Gilead Sciences's Scope 3 emissions surged to 38 Kt (+5.1/+16% y-o-y). The growth accelerated relative to the long-term trend (+6.1% CAGR) observed since 4Q'16.

The company is committed to reducing Scope 1 + 2 by 46% by 2030 from a base year 2019, which translates into the estimated reduction of -4.5 Kt per annum over the period of FY2021 - FY2030. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Company environmental metrics

Show more...